Free beta access. 5 free AI tokens each week. Optional top-ups available. See what is included
Opening Word document…

Gene Editing is K2 Innovation

Sinha 22. (Sinha, [Rohit, Head of Cryptography at Swirlds Labs.] [ARK2] "A CRISPR Framework for Emerging Biotechnology Applications: A Proposal to Separate Science from Politics." J. Health & Biomedical L. 18 (2022): 142. bin/get_pdf.cgi?handle=hein.journals/jhbio18&section=11. shARK)

Nevertheless, because genetic engineering of humans has a place in the biotech industry, the infuence of leading scientists must still vie with the influence of business. Companies built on the very foundation of genome editing tools are being funded 22 Royal Road by wealthy investors and intrinsically propelled by eager scientists who wish to expand the horizons of genetic engineering. In April 2015, the market for biotechnology companies utilizing the CRISPR/Cas9 system within the human health sector was estimated to be $46 billion (van Erp et al. 88). The main interests of these markets include “gene-therapy, cell-therapy, immunotherapy, fast and efcient development of transgenic research animals, drug discovery, as well as target validation and screening” (88). At least 14 diferent companies have been identified in furthering these interests—not including the accessory companies like Twist Bioscience that actually synthesize DNA sequences for CRISPR/Cas9 targeting. Many of these companies have predicted the advancements of genetic engineering in human cells and have been accruing capital since before human applications of CRISPR/Cas9 have even been published. Similar to how business has dominated the pharmaceutical industry, its influence is closing in on the newly established market of genetic engineering. The looming threat of business’s influence on genetic engineering industries presents further complexity for the establishment regulation. Since the biotech industry is in its infancy, critically relevant healthcare and business policies have not yet been set. For example, in terms of novel drug discovery, the pharmaceutical industry requires rigorous conditions to be met before drug approval (Eisenberg 477-491). Furthermore, high demands for new therapies have resulted in noncompliance to existing standards. In his book, Corporate Crime in the Pharmaceutical Industry, John Braithwaite—an expert on business regulation and a distinguished professor at Australian National University—writes about issues such as these. Braithwaite states, “The pharmaceutical industry has a worse record of international bribery and corruption than any other industry, a history of fraud in the safety testing of drugs, and a disturbing record of criminal negligence in the unsafe manufacture of drugs” (5-6). Criminal behavior in an industry responsible for the health of human beings is reprehensible. The pharmaceutical industry parallels genetic engineering of human beings in how they both affect human health. Since health concerns cannot deter criminal behavior in the pharmaceutical industry, it is possible a similar trend will be observed in the human health sector of the biotech industry. Moreover, infringement of business may not always be illegal even if it is inherently wrong. Recall when Mylan, the manufacturer of the EpiPen—a treatment necessary to save lives—risked many lives in raising the price of the emergency treatment to $600 in order to maximize proft during a lag in FDA approval for alternative, generic forms ("O'Toole Calls on FDA to Approve Generic EpiPens to Combat Mylan's Monopoly on Market"). Dr. James Baker, the CEO and chief medical ofcer of the advocacy group Food Allergy and Research Education, reluctantly reports, “Is Mylan doing anything illegal? No, it's taking advantage of all these things to take the market and basically push it to an extreme” (qtd. in Lupkin). Problems like these mirror future expectations for the market of genetic engineering. Once businesses have leverage in a particular market, it is their goal to maximize proft, even if it is at the expense of others’ lives. An economist from Indiana University and Ameritech Chair of Economic Development, David B. Audretsch, suggests: To generate a successful regional cluster, the existence of world class scientific talent is a necessary condition. However, it is not a sufficient condition. The ancillary or complementary factors must also be available to translate this knowledge into a commercialized product. The complementary factors include the presence of venture capital and other forms of finance, the existence of an entrepreneurial culture, and transparent and minimal regulations fostering the start-up and growth processes. (3) Since science sparked the market of genetic engineering, businesses now have the capacity to continue without the impediment of harsh, legal restrictions. Also, since gene-editing technology is democratizing the practice of genetic engineering, it will only require a degree of training for basic procedures to be accomplished. In conclusion, the open market or “laissez faire” 24 Royal Road approach to business in America conflicts with any progress made to reduce democratization of CRISPR.

Sign in to recut, update, or save this card.